Alexander Hillisch

Head of Global CADD

UCB BioSciences GmbH

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Alexander Hillisch is the Head of Global CADD at UCB BioSciences GmbH in Germany. His research primarily focuses on the development of small-molecule inhibitors for various therapeutic applications, including treatments for sepsis-induced coagulopathy and thromboembolic disorders. He has contributed to recent studies on targeting RNA sites in viral helicases and evaluating the role of machine learning in pharmacological modeling.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (9)

Jan Beránek

University of Chemistry and Technology, Prague

CZECH REPUBLIC

View details

Vittorio Katis

University of Oxford

UNITED KINGDOM

View details

Kristina Edfeldt

Karolinska Institutet

SWEDEN

View details

Andrew Leach

Head of Chemical Biology & Head of Industry Partnerships

European Bioinformatics Institute

UNITED KINGDOM

View details

Robert A. Batey

University of Toronto

CANADA

View details

Timothy Willson

Professor

University of North Carolina at Chapel Hill

UNITED STATES

View details

Cristian Bologa

Research Professor

University of New Mexico

UNITED STATES

View details

Casper Svendsen

Aalborg University

DENMARK

View details

Yoshua Bengio

Université de Montréal

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alexander Hillisch

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

CACHE Challenge #2

Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy.

Author Correction: Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants.

CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson's Disease Associated Protein.

Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants.

Target 2035 – an update on private sector contributions

Cyclobutane-bearing restricted anchoring residues enabled geometry-specific hydrocarbon peptide stapling.

Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.

CACHE (Critical Assessment of Computational Hit-finding Experiments): A public–private partnership benchmarking initiative to enable the development of computational methods for hit-finding

Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints.

Collaborators (9)

Jan Beránek

Vittorio Katis

Kristina Edfeldt

Andrew Leach

Robert A. Batey

Timothy Willson

Cristian Bologa

Casper Svendsen

Yoshua Bengio

Make your next move.